Explore this post with your favourite AI tool:
Share this article with AI tools to summarise, remember, or explore the content further.
Breakthroughs in mesothelioma treatment research are offering new hope for patients suffering from this aggressive cancer, which remains a significant concern for UK dutyholders managing legacy asbestos risks. Researchers at the University of Leicester have identified specific genetic markers that could lead to more personalised and effective therapies for those exposed to asbestos fibres.
The study, led by a team at the University’s Leicester Cancer Research Centre, focuses on the diverse genetic landscape of pleural mesothelioma. By categorising the disease into distinct molecular subtypes, the researchers have moved closer to a “precision medicine” approach. This shifts the focus away from a one-size-fits-all treatment model toward targeted interventions that address the specific biological drivers of an individual’s tumour.
For health and safety professionals and building dutyholders, the findings serve as a stark reminder of the long-term consequences of asbestos exposure. Despite the 1999 ban on all forms of asbestos in the UK, the long latency period of the disease—often spanning 20 to 50 years—means that the peak of mesothelioma deaths is only now being navigated. Advancements in medical science are becoming increasingly critical as the “asbestos legacy” continues to impact the UK workforce and those living in older housing stock.
The role of genetics in mesothelioma treatment research
The University of Leicester team utilised advanced genomic sequencing to analyse samples from patients across the country. Their work found that mesothelioma is not a uniform disease but rather a complex collection of different “clusters” with unique genetic mutations. This discovery explains why some patients respond well to standard chemotherapy and immunotherapy while others see little to no benefit.
By identifying these specific genetic vulnerabilities, clinicians can better predict which patients are likely to benefit from existing drugs and which should be enrolled in clinical trials for newer, experimental therapies. This branch of mesothelioma treatment research is vital because the disease progresses rapidly, often leaving a very narrow window for effective medical intervention once symptoms appear.
Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester, noted that the study provides a “comprehensive map” of the genomic changes that drive the cancer. This mapping allows researchers to identify “druggable” targets—specific proteins or pathways that can be inhibited by medicine—which were previously unknown in the context of asbestos-related cancers.
Implications for asbestos management and compliance
From a compliance perspective, the ongoing severity of the mesothelioma crisis reinforces the importance of the Control of Asbestos Regulations 2012 (CAR 2012). While mesothelioma treatment research focuses on the clinical end of the spectrum, the duty to manage asbestos in non-domestic premises remains the primary line of defence in the workplace. Facilities managers and building owners must ensure that asbestos-containing materials (ACMs) are identified, recorded, and managed to prevent the very exposure that leads to these medical diagnoses.
The reality is that many individuals currently being diagnosed were exposed decades ago, often in industrial settings or through maintenance work on poorly managed buildings. The fact that medical science is still struggling to find a definitive cure underscores the “zero tolerance” approach required for current asbestos safety. If an asbestos survey is out of date or a management plan is not being followed, the risk to contractors and occupants is not just a theoretical regulatory breach—it is a potential death sentence that medical science is still working hard to mitigate.
Furthermore, the high cost of mesothelioma claims and the long-term liability associated with asbestos exposure continue to affect the insurance and legal sectors. As mesothelioma treatment research improves survival rates, the nature of care and the associated costs for long-term treatment may also change, potentially impacting how businesses and insurers quantify future risks related to legacy asbestos.
Practical challenges for the construction and FM sectors
For those on the front line of property management, the medical developments at Leicester highlight the importance of “competent person” requirements. When asbestos is disturbed during refurbishment or demolition, the fibres released are invisible and odourless, yet they trigger the cellular changes studied by genomic researchers. There is no known safe limit of exposure, and the aggressive nature of the disease highlights why shortcuts in the removal process are so dangerous.
Training remains a cornerstone of safety. Workers must understand that even with advancements in mesothelioma treatment research, the prognosis for the disease remains challenging. Ensuring that staff have the correct Category A (Awareness), Category B (Non-licensable), or Category C (Licensable) training is not just about ticking a box; it is about preventing the specific genetic damage that the University of Leicester is currently investigating.
The research also sheds light on the “environmental” exposure risks that property managers must consider. While much of the historical focus was on heavy industry, cases are increasingly appearing in people who worked in schools, hospitals, and offices. This reinforces the need for robust inspection regimes and the maintenance of accurate asbestos registers that are readily accessible to any contractor entering a site.
Looking toward a targeted future
The transition toward personalised medicine represents the next frontier in tackling the asbestos crisis. As the University of Leicester continues to refine its findings, the hope is that mesothelioma can eventually be managed as a chronic condition rather than an acutely terminal one. This requires a sustained investment in mesothelioma treatment research and a willingness to integrate genetic testing into standard diagnostic pathways.
For now, the health and safety community must remain vigilant. While the medical profession works to improve the outcomes for those already affected, the responsibility to prevent future cases lies solely with those who manage the built environment. Effective risk assessment, clear communication of asbestos locations, and the safe management of materials in situ remain the only ways to ensure that future generations do not need to rely on these medical breakthroughs.
The work in Leicester is a significant step forward, but it serves as a sobering reminder that the asbestos problem in the UK is far from over. As researchers continue to deconstruct the genetic makeup of this silent killer, the industry must continue its efforts to keep the fibres contained and out of the lungs of workers and the public alike.
